bluuebunny/crossref_metadata_2025_split huggingface dataset:
Investigating the prevalence and correlates of anxiety and depression among patients with COVID-19 with and without concomitant tumor conditions.
Authors: Luo Qiong , Liu Haiyu , Zheng Qixian , Zhang Qianyuan , Zhang Suyun , Weng Guizhen , Chen Xiangqi , Yang Sheng 
Published: June 2024

e24090 Background: This study aims to assess the prevalence of anxiety and depression among patients diagnosed with novel coronavirus pneumonia, with and without concurrent tumor, identifying associated factors to offer empirical data and theoretical foundations for enhancing therapeutic strategies and life quality for this demographic. Methods: 74 patients diagnosed with novel coronavirus pneumonia were randomly selected from the Respiratory and Critical Care Medicine and Oncology departments of Fujian Medical University Affiliated Union Hospital between January 3 and March 18, 2023. Scale scores were employed, including the Hospital Anxiety and Depression Scale, Medical Coping Modes Questionnaire, Social Support Rating Scale, and Type D Personality Scale. Additionally, routine blood analyses at admission were conducted to compute the Neutrophil to Lymphocyte Ratio (NLR). Anxiety and depression prevalence were compared between groups with and without tumors, and correlations were examined with other scale scores and NLR. Results: Among the 74 patients with novel coronavirus pneumonia, 14 with tumors exhibited a 64.29% incidence rate for anxiety and depression, while 60 without tumors presented a 33.33% rate, signifying a statistically significant discrepancy (P < 0.05). Notable differences were observed in social support and NLR between groups (P < 0.05), though coping methodologies and Type D personality distributions showed no statistical variance (P > 0.05). Conclusions: Novel coronavirus pneumonia patients with tumors demonstrate a markedly elevated incidence of anxiety and depression, influenced by social support and NLR. Early implementation of psychological and pharmacological interventions could potentially mitigate these conditions, enhancing life quality and clinical outcomes for this population and meriting further investigative exploration.
Can narrative medicine methods improve well-being in patients with gastrointestinal malignancy?
Authors: Makoff Eve Louise , Rehman Rabia , Li Ming , Iqbal Syma 
Published: June 2024

e24091 A Pilot study - Can Narrative Medicine Methods Improve Well-being in Patients with Gastrointestinal Malignancy? Background: Patients with cancer often face profound physical and emotional challenges. Narrative medicine methods, involving discussions of and writing about creative texts, are utilized to help healthcare providers improve communication and process emotional experiences which, unexplored, may lead to poor well-being. We apply the narrative medicine method to patients with GI malignancies. Methods: The endpoints of this pilot study were feasibility - 7/10 participants completing 2 out of 3 sessions, and assessing the benefit of applying the practice to optimize well-being. 10 patients were identified by a single oncologist at USC/Norris cancer center to undergo three narrative medicine sessions. Sessions addressed themes relevant to well-being: Identity, Meaning making, and Finding joy. A survey with Likert scales (1-5) and free text answers, as well as interviews, were administered. Content analysis was done. ESAS scales were administered before sessions. Results: 7 of 10 patients have been assessed, completing all three sessions.Surveys were administered after session 3, interviews 1 month later. 5 was the most popular Likert choice. 7/7 chose a 5 for feeling comfortable and learning about themselves. In free text answers, 6/7 patient responses reflected themes of enhanced self-reflection, 2/7 improved perspective-taking, and 3/7 enhanced empathy for others. 1/7 said the sessions gave them hope for medical research, and 1/7 noted the sessions helped them tolerate chemotherapy. ESAS scores trending in a positive direction included pain, drowsiness, nausea, anxiety, and well-being. The interviews elicited the following themes: 7/7 noted the narrative medicine experience had been enjoyable, 6/7 noted enhanced meaning-making meaning and perspective-taking. 3/7 noted the sessions made them feel more positively about their healthcare experiences and helped them embrace their identities outside of cancer. 3/7 said the sessions improved their empathy for others. Other individual themes were: the sessions gave them hope, helped with self-reflection, encouraged seeking new experiences, helped them accept circumstances, enhanced connection to creativity and spirituality, and improved their ability to connect to others. Conclusions: This narrative medicine pilot project was feasible and patients were able to complete the assessment. The evaluative scores demonstrated that all participants felt comfortable participating. Additionally, the patients noted benefits related to well-being including but not limited to improved capacity for self-reflection, putting things in perspective, meaning-making, and noticing moments of joy. A larger study is planned to assess the benefits of this approach for patient well-being and clinical outcomes.
Assessment of chemotherapy-induced nausea and vomiting in adult patients with hematopoietic stem-cell transplant at a tertiary care hospital.
Authors: Alanazi Ahmed , AlRajhi Abdullah M. , Alnakhli Adel , Bashir Mohammed Salman , Alnajjar Fouad 
Published: June 2024

e24098 Background: Chemotherapy induced nausea and vomiting (CINV) is prevalent and potentially treatment-limiting side effects in cancer patients.1 Nausea and vomiting are frequent and significantly affect cancer patients' daily functioning and health-related quality of life (HRQL). A patient who experienced nausea and vomiting showed to be affected by worse physical, cognitive, social functioning, and global quality of life in comparison to patients who don’t have nausea and vomiting. Methods: We conducted a prospective cohort observational study to assess the complete response (CR) and risk factor associated with nausea and vomiting among HSCT patients at King Fahad Medical City (KFMC). All adult patient underwent Bone Morrow Transplant (BMT) were included in the study. Data was collected prospectively during admission to the hospital and receive the conditioning regimen. Patients was interviewed by clinical pharmacist and assessed using MASCC Antiemesis Tool© (MAT) to assess the effectiveness of our regimen used to prevent nausea and vomiting during active chemotherapy days and delayed phase. Results: A total of 30 patients were enrolled in the study during a one year follow up from April 2021 to April 2022. Data analysis was done and revealed as follows; out of 30 patients enrolled 18 (60%) patients were female while 12 (40%) were male. Lymphomas including (Non-Hodgkin, and Hodgkin lymphomas) were the most common diagnosis included among patients 17 (56.6%). BEAM protocol was the most common conditioning regimen protocol used 13 (43.3%). Complete response (CR) was achieved in 13 (43.3%) patients during acute nausea and vomiting, while 17 (56.7%) patients weren’t being able to achieve CR. Furthermore, out of the 30 patients observed, 6 (20.0%) experienced delayed vomiting, while 19 (63.3%) experienced delayed nausea. Similarly, Complete response (CR) was achieved in 11 (36.7%) patients during delayed nausea and vomiting, while 19 (63.3%) patients weren’t being able to achieve Complete response (CR) respectively. Breakthrough medication for nausea and vomiting was needed in all patients who didn’t have to achieve CR 19 (63.3%) patients. There was no association between age, gender, conditioning regimen, and type of transplant and achieved CR among patients (P- value; > 0.05). However, more breakthrough medication is needed when CR is not achieved (P- value; < 0.05). Conclusions: At our institution, among hematopoietic transplant recipients receiving appropriate antiemetics, approximately half (50%) achieved complete response (CR) in preventing chemotherapy-induced vomiting (CINV). Age, gender, and transplant type were not significantly associated with increased CR failure, while the specific conditioning regimen did not show a statistically significant impact.
International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor.
Authors: Giordano Antonio , Ignatiadis Michail , Barrios Carlos H. , Bidard Francois Clement , Xu Binghe , Vana Alicia M , Gong Jason , Holynskyj Ariadna , Gopalakrishna Prashanth , Rugo Hope S. 
Published: June 2024

TPS1129 Background: Substantial improvement in survival outcomes has been achieved with cyclin-dependent kinase (CDK) 4/6 inhibitors plus endocrine therapy (ET) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced/metastatic breast cancer (BC); however, resistance to this therapy ultimately occurs. PF-07220060 is an oral, highly potent, selective, next generation inhibitor of CDK4 with sparing of CDK6. A first-in-human phase 1/2a study evaluated PF-07220060 (300/400 mg BID) plus ET in patients with HR+/HER2− advanced/metastatic BC who progressed on a prior CDK4/6 inhibitor plus ET (n = 26). At the data cutoff date of November 1, 2022, in patients with measurable disease (n = 21), 6 (29%) had confirmed objective response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, and 11 (52%) had a clinical benefit response (CBR). Of all patients (n = 26), median progression-free survival (PFS) was 24.7 weeks, and 8 (31%) patients continued treatment without progression for 60 or more weeks (1). Methods: This international (29 countries; 356 proposed sites), phase 3, open-label, randomized, parallel-group clinical trial will evaluate whether PF-07220060 plus fulvestrant improves clinical outcomes compared with the investigator-chosen therapies in adult female and male patients with HR+/HER2− advanced/metastatic BC with progression after prior therapy of CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor.Key eligibility criteria include advanced/metastatic BC with measurable disease or non-measurable bone-only disease, documented HR+/HER2− status, and progressive disease/recurrence during or within 12 months after the last dose of prior CDK4/6 inhibitor given in the advanced or adjuvant setting, respectively. One additional prior line of approved treatment in the advanced setting targeting ESR1, PIK3CA, AKT1, PTEN, or BRCA is allowed. Approximately 500 patients will be randomly assigned (1:1) to receive PF-07220060 (orally and continuously in a 28-day cycle) plus fulvestrant (intramuscular injection on days 1 and 15 of cycle 1 and then on day 1 of each cycle thereafter) or investigator’s choice of fulvestrant alone or everolimus plus exemestane, which must be declared before randomization. The primary endpoint is PFS by blinded independent central review, which is defined as the time from the date of randomization to the date of first documented disease progression, as determined per RECIST v1.1, or death due to any cause, whichever occurs first. Secondary objectives include overall survival, OR, duration of response, CBR, safety, patient-reported outcomes, and pharmacokinetics. 1. Yap. JCO. 2023;41:3009. Clinical trial information: NCT06105632 .
TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.
Authors: Cabel Luc , Loirat Delphine , Martin Babau Jerome , Bello Diana , Pierga Jean-Yves , Lerebours Florence , Ezzili Cyrine , Berger Frederique , Bidard Francois Clement 
Published: June 2024

TPS1142 Background: Sacituzumab govitecan (SG) is an anti-TROP2 antibody-drug conjugate (ADC) with an SN-38 payload (topoisomerase I inhibitor) that was recently approved for use in advanced triple-negative breast cancer (TNBC). The rapid spontaneous linker hydrolysis in sacituzumab-govitecan releases a very large amount of SN-38 cargo systemically, which may in part contribute to efficacy and also in part be responsible for systemic side effects (1). PLX038 is a 40 kDa 4-arm PEG-SN38 conjugate with a half-life of 5 days. It has a controlled, slow-release rate which allows high SN-38 exposure over an extended period of time with a low Cmax, and very low levels of SN-38-glucuronide. The PLX038 nanomolecule also penetrates large pores of tumor vasculature, and accumulates and is retained in the tumor for long periods. The prolonged exposure of tumors to SN-38 may result in increased efficacy without resulting in severe gastrointestinal toxicity. We hypothesize that PLX038 may be effective in patients with advanced TNBC who have been previously treated with standard chemotherapy regimens. Methods: This is an open label, multi-centric phase II study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of PLX038 in locally advanced or metastatic TNBC previously treated with at least two prior cytotoxic chemotherapy regimens for locally advanced or metastatic breast cancer including an anthracycline, taxane and sacituzumab govitecan. Patients will be treated at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection) after at least a first cycle at 1300mg/m2. At the discretion of the treating physician, the PLX038 dose will be increased to 1730 mg/m2 for patients who tolerate at least 1 cycle. All included patients will receive PLX038 as single agent as long as study is ongoing or until progression of disease, unacceptable toxicity, patient withdrawal of consent, Investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor. The primary endpoint is the best tumor response (defined as partial or complete response in the first 6 months of treatment) assessed by investigators per RECIST v1.1 criteria, with tumor assessments every 8 weeks (± 7 days). Secondary endpoints include i) efficacy criteria (time to response, duration of response, progression-free survival, overall survival), ii) toxicity criteria (AE/SAEs), iii) association between PLX038 efficacy and biomarkers (homologous recombination defect, replication stress-related biomarkers such as SFLN11 expression, RB1 loss), iv) PK/PD analysis. A Simon's two-stage optimum design will be used, and a maximum of N=44 patients will be included, 1. Santi et al., Biodrugs 2024. Clinical trial information: NCT06162351 .
Mating-induced Ecdysone in the testis disrupts soma-germline contacts and stem cell cytokinesis
Authors: Roach Tiffany V. , Lenhart Kari F. 
Published: June 2024

ABSTRACT
Germline maintenance relies on adult stem cells to continually replenish lost gametes over a lifetime and respond to external cues altering the demands on the tissue. Mating worsens germline homeostasis over time, yet a negative impact on stem cell behavior has not been explored. Using extended live imaging of the Drosophila testis stem cell niche, we find that short periods of mating in young males disrupts cytokinesis in germline stem cells (GSCs). This defect leads to failure of abscission, preventing release of differentiating cells from the niche. We find that GSC abscission failure is caused by increased Ecdysone hormone signaling induced upon mating, which leads to disrupted somatic encystment of the germline. Abscission failure is rescued by isolating males from females, but recurs with resumption of mating. Importantly, reiterative mating also leads to increased GSC loss, requiring increased restoration of stem cells via symmetric renewal and de-differentiation. Together, these results suggest a model whereby acute mating results in hormonal changes that negatively impact GSC cytokinesis but preserves the stem cell population.
The novel Plasmodium berghei protein S14 is essential for sporozoite gliding motility and infectivity
Authors: Ghosh Ankit , Varshney Aastha , Narwal Sunil Kumar , Nirdosh  , Gupta Roshni , Mishra Satish 
Published: June 2024

ABSTRACT
Plasmodium sporozoites are the infective forms of the malaria parasite in the mosquito and vertebrate host. Gliding motility allows sporozoites to migrate and invade mosquito salivary glands and mammalian hosts. Motility and invasion are powered by an actin–myosin motor complex linked to the glideosome, which contains glideosome-associated proteins (GAPs), MyoA and the myosin A tail-interacting protein (MTIP). However, the role of several proteins involved in gliding motility remains unknown. We identified that the S14 gene is upregulated in sporozoite from transcriptome data of Plasmodium yoelii and further confirmed its transcription in P. berghei sporozoites using real-time PCR. C-terminal 3×HA–mCherry tagging revealed that S14 is expressed and localized on the inner membrane complex of the sporozoites. We disrupted S14 in P. berghei and demonstrated that it is essential for sporozoite gliding motility, and salivary gland and hepatocyte invasion. The gliding and invasion-deficient S14 knockout sporozoites showed normal expression and organization of inner membrane complex and surface proteins. Taken together, our data show that S14 plays a role in the function of the glideosome and is essential for malaria transmission.
Promotional Inventory Displays: An Empirical Analysis Using IoT Data
Authors: Zeng Jacob Z. , Agarwal Ashish , Stamatopoulos Ioannis 
Published: June 2024

Problem definition: Despite their widespread use, promotional inventory displays’ campaign execution is opaque. Brands (manufacturers) can only verify in-store display presence through manual, on-site audits, which are costly and limited in scope. This lack of visibility into execution makes it difficult for brands to quantify the sales impact of displays and properly evaluate campaign performance. Methodology/results: We use Internet-of-Things (IoT)-generated data on the real-time location of about 15,000 displays from 10 display campaigns in about 5,000 stores of a Fortune 500 retail chain, paired with the stores’ point-of-sale (POS) data between September 2017 and March 2018, to measure the operational execution and effectiveness of display campaigns. First, we find that campaigns are poorly executed: 29% of displays never made it to a store’s floor, and those that made it only spent 62% of the campaign there. Second, we find that poor execution deprives brands of substantial sales, especially during campaign weeks: placing a display on the floor during an arbitrary week increases the targeted products’ sales by 7.3%, and placing it on the floor during a campaign week boosts sales by another 2.3%. Managerial implications: Our results enable brands to optimize investments in promotional display campaigns and execution. We project that brands would suffer a 3.1% dollar sales decrease during campaign weeks by discontinuing current campaigns. However, they could achieve up to a 6.9% dollar sales increase during campaign weeks through improved execution. Supplemental Material: The online appendix is available at https://doi.org/10.1287/msom.2022.0291 .
Multidetector computer tomography and magnetic resonance imaging of double superior mesenteric veins: A case report
Authors: Tang Wei , Peng Song 
Published: June 2024

BACKGROUND
This study aimed to describe the findings of double superior mesenteric veins (SMVs), a rare anatomical variation, on multidetector computer tomography (MDCT) and magnetic resonance imaging (MRI) images.
CASE SUMMARY
We describe the case of a 34-year-old male, who underwent both MDC and MRI examinations of the upper abdomen because of liver cirrhosis. MDCT and MRI angiography images of the upper abdomen revealed an anatomic variation of the superior mesenteric vein (SMV), the double SMVs.
CONCLUSION
The double SMVs are a congenital abnormality without potential clinical manifestation. Physicians need to be aware of this anatomical variation during abdominal surgery to avoid iatrogenic injury.
TWO- TO FIVE-YEAR OUTCOMES OF 503 FIXED-BEARING ANKLE ARTHROPLASTIES
Authors: Townshend D. , Bing A. , Clough T. , Sharpe I. , Blundell C. , Davenport J. , Davies H. , Davis J. , Dhar S. , Goldberg A. , Karski M. , Hepple S. , Kakwani R. , McKinley J. , Murty A. , Ragland M. , Shalaby H. , Smith R. , Taylor H. 
Published: June 2024

IntroductionThis is a multi-centre, prospective, observational study of 503 INFINITY fixed bearing total ankle arthroplasties. We report the minimum two-year results of this prosthesis which was introduced to the UK Market in 2014 and is now the most used ankle arthroplasty in the National Joint Registry of England and Wales.MethodsPatients were recruited from 11 centres in the United Kingdom between June 2016 and November 2019. Demographic, radiographic, and functional outcome data (Ankle Osteoarthritis Scale, Manchester Oxford Foot Ankle Questionnaire and Euroquol 5D-5L) were collected preoperatively, at 6 months, 1 year and 2 years and 5 years. The average age was 67.8 (range 23.9 to 88.5) and average BMI 29.3 (18.9 to 48.0). The COFAS grading system was used to stratify deformity. There were 261 (51.9%) COFAS Type 1, 122 (24.2%) COFAS Type 2, 31 (6.2%) COFAS 3 and 89 (17.7%) COFAS type 4. 38 patients (7.6%) presented with inflammatory arthritis. 99 (19.7%) implantations utilised patient specific instrumentation. Complications and reoperations were recorded as adverse events. Radiographs were assessed for lucencies, cysts and/or subsidence.ResultsThe mean follow up was 34.2 months (range 24–64). 15 patients have died, 8 withdrawn and 3 lost to follow up. 8 implants (1.6%) have been revised. According to the Glazebrook classification there were low grade complications in 6.6%, medium grade in 1.4% and high grade in 1.6%. There have been an additional 13 non revision re-operations (2.6%) at the latest follow up. There was a significant (p < 0.01) improvement across all functional outcome scores at a minimum of 2yr follow up.Discussion and conclusionThis large cohort has shown a low early revision rate and high functional outcomes with a low-profile fixed bearing prosthesis.